HomeCompareAVGR vs ARCC

AVGR vs ARCC: Dividend Comparison 2026

AVGR yields 421.94% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVGR wins by $204.1K in total portfolio value
10 years
AVGR
AVGR
● Live price
421.94%
Share price
$0.47
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$228.6K
Annual income
$477.83
Full AVGR calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — AVGR vs ARCC

📍 AVGR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVGRARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVGR + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVGR pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVGR
Annual income on $10K today (after 15% tax)
$35,864.98/yr
After 10yr DRIP, annual income (after tax)
$406.16/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, AVGR beats the other by $405.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVGR + ARCC for your $10,000?

AVGR: 50%ARCC: 50%
100% ARCC50/50100% AVGR
Portfolio after 10yr
$126.6K
Annual income
$239.49/yr
Blended yield
0.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

AVGR
Analyst Ratings
4
Buy
3
Hold
Consensus: Buy
Altman Z
-48.2
Piotroski
4/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVGR buys
0
ARCC buys
0
No recent congressional trades found for AVGR or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVGRARCC
Forward yield421.94%10.65%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%-50%
Portfolio after 10y$228.6K$24.5K
Annual income after 10y$477.83$1.14
Total dividends collected$131.1K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: AVGR vs ARCC ($10,000, DRIP)

YearAVGR PortfolioAVGR Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$31,797$21,097.05$11,373$532.74+$20.4KAVGR
2$65,370$31,346.90$12,608$279.46+$52.8KAVGR
3$100,060$30,114.17$13,809$142.90+$86.3KAVGR
4$128,604$21,539.72$15,042$72.20+$113.6KAVGR
5$150,543$12,936.60$16,341$36.27+$134.2KAVGR
6$168,157$7,076.40$17,732$18.18+$150.4KAVGR
7$183,622$3,693.63$19,231$9.10+$164.4KAVGR
8$198,360$1,884.73$20,851$4.55+$177.5KAVGR
9$213,196$951.40$22,605$2.28+$190.6KAVGR
10$228,598$477.83$24,504$1.14+$204.1KAVGR

AVGR vs ARCC: Complete Analysis 2026

AVGRStock

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.

Full AVGR Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this AVGR vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVGR vs SCHDAVGR vs JEPIAVGR vs OAVGR vs KOAVGR vs MAINAVGR vs HTGCAVGR vs GBDCAVGR vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.